128 related articles for article (PubMed ID: 9187266)
1. Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A.
Jacobitz S; Ryan MD; McLaughlin MM; Livi GP; DeWolf WE; Torphy TJ
Mol Pharmacol; 1997 Jun; 51(6):999-1006. PubMed ID: 9187266
[TBL] [Abstract][Full Text] [Related]
2. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
4. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
5. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
[TBL] [Abstract][Full Text] [Related]
7. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
8. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.
Saldou N; Obernolte R; Huber A; Baecker PA; Wilhelm R; Alvarez R; Li B; Xia L; Callan O; Su C; Jarnagin K; Shelton ER
Cell Signal; 1998 Jun; 10(6):427-40. PubMed ID: 9720765
[TBL] [Abstract][Full Text] [Related]
9. Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis.
Cheung PP; Yu L; Zhang H; Colman RW
Arch Biochem Biophys; 1998 Dec; 360(1):99-104. PubMed ID: 9826434
[TBL] [Abstract][Full Text] [Related]
10. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast.
Torphy TJ; Stadel JM; Burman M; Cieslinski LB; McLaughlin MM; White JR; Livi GP
J Biol Chem; 1992 Jan; 267(3):1798-804. PubMed ID: 1309798
[TBL] [Abstract][Full Text] [Related]
11. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
12. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
Souness JE; Rao S
Cell Signal; 1997; 9(3-4):227-36. PubMed ID: 9218122
[TBL] [Abstract][Full Text] [Related]
13. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
[TBL] [Abstract][Full Text] [Related]
14. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain.
Jin SL; Swinnen JV; Conti M
J Biol Chem; 1992 Sep; 267(26):18929-39. PubMed ID: 1326538
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.
Liu S; Laliberté F; Bobechko B; Bartlett A; Lario P; Gorseth E; Van Hamme J; Gresser MJ; Huang Z
Biochemistry; 2001 Aug; 40(34):10179-86. PubMed ID: 11513595
[TBL] [Abstract][Full Text] [Related]
17. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.
Huston E; Lumb S; Russell A; Catterall C; Ross AH; Steele MR; Bolger GB; Perry MJ; Owens RJ; Houslay MD
Biochem J; 1997 Dec; 328 ( Pt 2)(Pt 2):549-58. PubMed ID: 9371714
[TBL] [Abstract][Full Text] [Related]
19. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities.
Rocque WJ; Tian G; Wiseman JS; Holmes WD; Zajac-Thompson I; Willard DH; Patel IR; Wisely GB; Clay WC; Kadwell SH; Hoffman CR; Luther MA
Biochemistry; 1997 Nov; 36(46):14250-61. PubMed ID: 9369498
[TBL] [Abstract][Full Text] [Related]
20. Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells.
Owens RJ; Catterall C; Batty D; Jappy J; Russell A; Smith B; O'Connell J; Perry MJ
Biochem J; 1997 Aug; 326 ( Pt 1)(Pt 1):53-60. PubMed ID: 9337850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
